MODD stock forecast, quote, news & analysis

Key Takeaways

• Modular Medical (MODD) shares fell approximately 13.7% over the last 30 days, from about $2.26 to $1.95, amid persistent dilution concerns and an unproven commercial revenue trajectory.
• The decline extends a longer slide: the stock is down roughly 30% over the trailing three months and traded above $4.60 as recently as early July.
• Modular Medical remains pre-revenue, with a limited cash balance, a going-concern warning, and active equity fundraising that has expanded its share count and pressured the stock.
• Positive milestones — FDA clearance enhancements, a national pharmacy benefit manager contract, and an October commercial launch of the Pivot pump — have been overshadowed by balance-sheet and execution risk.

Modular Medical (MODD) Company Overview and Market Position

Modular Medical, Inc. is a San Diego-based medical device company focused on next-generation insulin delivery technology for people living with diabetes. Founded in 1998 by Paul DiPerna — who previously founded Tandem Diabetes Care and designed its t:slim pump — the company is led by CEO James "Jeb" Besser.

Its flagship product is the Pivot, a tubeless, wearable insulin patch pump with a removable two-part design and a 3 mL reservoir. The Pivot targets the large "almost-pumper" population: insulin-dependent adults who remain on multiple daily injections because of the cost, complexity, and usability barriers associated with traditional pumps. Pivot received FDA 510(k) clearance in April 2026 and reached commercial availability in June 2026, positioning Modular Medical as one of only a few companies with a fully electronic tubeless pump in the U.S. market.

Investors follow MODD for its exposure to the sizable diabetes-technology market, its differentiated low-cost design, and its transition from a development-stage to a commercial-stage company — though it competes against well-capitalized players such as Insulet (PODD) and Tandem Diabetes Care (TNDM).

Modular Medical (MODD) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, MODD declined from approximately $2.26 to $1.95, a drop of about 13.7%. The move was uneven: the stock briefly rebounded toward the $2.68–$2.73 range in early-to-mid October before giving back those gains and closing near $1.95 on October 20, 2026.

The quarterly picture is weaker. Over the trailing three months, MODD has fallen roughly 30% from its late-July level near $2.79. The stock began July above $4.60 before a sharp mid-July selloff, underscoring the high volatility that has characterized the name since its 1-for-30 reverse stock split in March 2026 and its subsequent Nasdaq compliance recovery.

What Drove MODD Stock Price in the Last 30 Days

The dominant factor weighing on MODD over the past month has been dilution and balance-sheet risk. Modular Medical is pre-revenue and reported a net loss of about $6.5 million for its fiscal first quarter ended June 30, 2026, with cash and cash equivalents of roughly $3.9 million at quarter-end. The company has repeatedly raised capital through an at-the-market facility and equity offerings, and its share count has expanded from roughly 4.7 million following the reverse split to more than 8 million, according to SEC filings and market data. This persistent equity issuance has created an overhang that has pressured the share price even as the company executes on its commercial plan.

Sentiment was also shaped by the transition to commercialization. In early September, the company announced FDA clearance for Pivot software enhancements and a contract with a national U.S. pharmacy benefit manager, which initially lifted the stock. However, those gains reversed quickly — shares fell more than 23% in a single session on September 8 — as investors weighed the company's thin liquidity and lack of revenue against its launch ambitions. The October rollout of the Pivot across five U.S. markets and related investor presentations provided limited relief, and the stock resumed its decline into late October.

What Drove MODD Stock Performance Over the Last Quarter

The broader multi-month decline reflects the market's reassessment of a development-stage company that is only now beginning to generate revenue. After the April FDA clearance and June commercial availability announcements, MODD traded at elevated levels, but a July selloff and subsequent drift lower showed investors demanding clearer evidence of adoption, reimbursement, and sales velocity.

Throughout the quarter, the company's going-concern disclosure, limited cash runway, and dependence on ongoing capital raises remained central concerns. Dilution risk scores from independent trackers have rated MODD at critical levels, and its outstanding warrants add further potential share-count pressure. While the Pivot's differentiated design and the underserved "almost-pumper" market remain compelling longer-term themes, the lack of proven revenue and the need for repeated financing have dominated the quarterly narrative and kept the stock under pressure.

Trending AI Robots

Tickeron's Trending AI Robots page is a curated hub where traders can explore AI-driven trading tools across the market. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only top-performing and most relevant bots are featured in this section, helping users cut through the noise. The bots vary widely in strategy, timeframe, and performance metrics, so the section is designed to let traders compare approaches and find tools that align with their own objectives. Whether you are tracking momentum, swing, or longer-horizon signals, exploring the Trending AI Robots page can offer a useful starting point for building a more systematic approach to the market.

MODD Stock Forecast Drivers: What Investors Should Watch Next

The most important near-term catalyst for Modular Medical is the execution of its October 2026 commercial launch across five U.S. markets, along with the first signs of real-world adoption and revenue from the Pivot pump. The company's next quarterly report — expected around November 13, 2026 — will provide an early read on launch trajectory and management commentary.

Investors should also monitor the company's cash position and any further financing activity, given the limited cash runway and ongoing dilution risk. Additional factors include reimbursement and payer coverage momentum, the pursuit of a European CE Mark, competitive developments from established insulin-pump makers, and any updates on the software roadmap toward automated insulin delivery features. As a pre-revenue company with a going-concern disclosure, Modular Medical's stock is likely to remain sensitive to both operational milestones and capital-structure developments.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations